CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
The VSV-EBOPLUS project investigates the immune responses elicited by the VSV-Zaire Ebola vaccine in adults and children. Using advanced systems biology techniques, it aims to understand the vaccine's efficacy, safety, and long-term immune responses across diverse populations.
The vesicular stomatitis virus (VSV)-Zaire Ebola vaccine (VSV-ZEBOV) is a recombinant vector-based vaccine in which the VSV envelope glycoprotein was replaced with the Zaire strain Ebola virus glycoprotein.
Within one year of the initiation of its clinical development, the VSV-ZEBOV vaccine has demonstrated safety, immunogenicity and a remarkably high protective efficacy against Ebola Virus Disease, using a high vaccine dose (2x107 pfu) in the WHO-sponsored VSV-ZEBOV ring-vaccination trial in ad…
SCLAVO VACCINES ASSOCIATION
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Switzerland, Geneve
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
United States, Whitehouse Station Nj
Type: Company (for-profit)
Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
SME: No
UGOT - GOETEBORGS UNIVERSITET/UNIVERSITY OF GOTHENBURG
Sweden, Goeteborg
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
Italy, Siena
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
Guests see up to 5 keywords.
